+293.7%
HPE vs MRNA
+806.0%
-512.3%
-54.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | +1.3% | -1.9% | -0.7% |
| 7D | -9.3% | -13.8% | +4.5% | -8.9% |
| 30D | -18.9% | -17.7% | -1.2% | -18.4% |
| 3M | -14.2% | +14.3% | -28.5% | -14.8% |
| 6M | +40.2% | +336.0% | -295.8% | +27.9% |
| YTD | +91.6% | +575.9% | -484.3% | +68.6% |
| 1Y | +124.8% | +724.4% | -599.6% | +94.9% |
| 3Y | +207.2% | +160.8% | +46.4% | +180.2% |
| 5Y | +262.0% | -24.4% | +286.5% | +237.6% |
| All | +293.7% | +806.0% | -512.3% | +239.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling